NCT07672223 Enlonstobart Non-small cell lung cancer stage IIIB Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07672223—A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07672223 is a hot trial to watch
Non-small cell lung cancer stage IIIB is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07672223 is notable because it evaluates Enlonstobart in a Phase 3 design while DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by IRC per RECIST 1.1 or death (whatever the cause). Recurrence of disease was defined as local regional recurrence or a distant (metastatic) recurrence, confirmed by imaging and/or pathology. A second primary NSCLC was also considered to be an event. serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07672223 |
| Official title | A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) |
| Phase / status | Phase 3 / Not yet recruiting |
| Intervention | Enlonstobart, SYS-6010, SYS6010, Nivolumab, Durvalumab, Pembrolizumab, Toripalimab ±+platinum-based doublet chemotherapy, Tislelizumab |
| Sponsor | CSPC Megalith Biopharmaceutial Co., Ltd. |
| Collaborators | Not reported |
| Geography | Not reported |
| Enrollment | 570 |
| Primary endpoint | DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by IRC per RECIST 1.1 or death (whatever the cause). Recurrence of disease was defined as local regional recurrence or a distant (metastatic) recurrence, confirmed by imaging and/or pathology. A second primary NSCLC was also considered to be an event. |
| Endpoint time frame | Up to approximately 60 months |
| Primary completion / readout proxy | [object Object] |
Design and endpoint interpretation
The phase label is only the starting point. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment. Planned enrollment of 570 participants across Not reported shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary: DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by IRC per RECIST 1.1 or death (whatever the cause). Recurrence of disease was defined as local regional recurrence or a distant (metastatic) recurrence, confirmed by imaging and/or pathology. A second primary NSCLC was also considered to be an event. (Up to approximately 60 months)
- Secondary: OS was defined as the time from randomization to the date of death(whatever the cause). (Up to approximately 60 months)
- Secondary: DFS was defined as the time from randomization to either the date of disease recurrence as assessed by investigators per RECIST 1.1 or death (whatever the cause). Recurrence of disease was defined as local regional recurrence or a distant (metastatic) recurrence, confirmed by imaging and/or pathology. A second primary NSCLC was also considered to be an event. (Up to approximately 60 months)
- Secondary: Incidence and severity of Adverse Events (AEs) (Approximately 15 months)
- Secondary: EORTC QLQ-30 questionnaire (Approximately 13 months)
Benchmark readouts in the surrounding field
- Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (Phase 2): Percentage of Participants Alive Without Local-regional Progression [Local-regional Progression-free (LRPF) Survival] at Two Years (NRG): P-Value = 0.6585; Percentage of Participants Alive Without Local-regional Progression [Local-regional Progression-free (LRPF) Survival] at Two Years (NRG): P-Value = 0.6585
- A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (Phase 2): Number of Participants With Surgical Delays = 0 Participants ; Number of Participants With Surgical Delays = 4 Participants
- AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) (Phase 2): PFS(Median) = 8.1 Months (95% Confidence Interval, 6.0 - 10.2); PFS(Median): Hazard Ratio (HR) = 0.99(95% CI, 0.74 - 1.33), P-Value = 0.4698
These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.
Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Enlonstobart (Approved; PD-1); SYS-6010 (Phase 3; EGFR C797S x EGFR T790M x EGFR-Ex19del)
Company & Deal Intelligence context: CSPC Megalith Biopharmaceutial Co., Ltd. — China — http://www.e-cspc.com
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.
Bottom line
NCT07672223 is a focused lens on Non-small cell lung cancer stage IIIB development. Its value will be determined by whether Enlonstobart can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
